NightBalance obtains reimbursement in the Netherlands for its innovative sleep apnea therapy - Gilde Healthcare

NightBalance obtains reimbursement in the Netherlands for its innovative sleep apnea therapy

December 22, 2017

The Hague, the Netherlands – NightBalance, a leader in innovative obstructive sleep apnea therapies, today announced that the Dutch National Health Care Institute (ZIN) issued a positive recommendation to include its sleep apnea therapy for reimbursement. The Sleep Position Trainer (SPT®), developed by NightBalance, treats Positional Obstructive Sleep Apnea (POSA) which affects half a million people in the Netherlands. The Dutch Ministry of Health, Welfare and Sport will formally approve inclusion of the SPT® following ZIN’s recommendation.

The approval is based on the company’s strong data, demonstrating clinical efficacy, which allowed NightBalance to successfully fulfil the high standards set by the reimbursement approval process in the Netherlands for new medical devices and therapeutics. The government’s decision allows health care insurers in the Netherlands to offer all Dutch citizens suffering from POSA the SPT® device as part of the basic insurance plan.

The ZIN approval is the recognition of ground-breaking work in building a solid clinical data set of more than 80,000 nights in peer reviewed published research, demonstrating the ease of use, efficacy, and cost-effectiveness of our therapy and the SPT® device. The SPT® offers a user-friendly alternative to current treatments with more convenience and comfort for the patient and less cost for the healthcare system.

 

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund.
Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America.
Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
Since 2001 Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
February 29, 2024

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent...
February 28, 2024

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125...
February 27, 2024